The 5-year relative survival rate of patients with ER+ metastatic disease is 24%, almost none are cured, and each year nearly 28,000 women in the United States with recurrent ER+ metastatic tumors die [2,3,9]. Here, ESR1 is linked to metastatic neoplasm.